TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20012912

Group type: EXPERIMENTAL
Intervention: Volume controlled low tidal volume ventilation plus medicated (saline + surfactant) BAL
Number of subjects: 44

Group type: COMPARATOR
Intervention: Volume controlled low tidal volume ventilation (Control Group)
Number of subjects: 44
Study: 18441037

Group type: EXPERIMENTAL
Intervention: Serial casting
Number of subjects: 26

Group type: COMPARATOR
Intervention: Positioning
Number of subjects: 26
Study: 16036424

Group type: EXPERIMENTAL
Intervention: Riluzole treatment
Number of subjects: 2069
Study: 11885789

Group type: EXPERIMENTAL
Intervention: Intracameral unpreserved lignocaine 1%
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 135
Study: 10358675

Group type: EXPERIMENTAL
Intervention: Enhanced tracking and follow-up services by community health workers
Number of subjects: 421

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 421
Study: 7547090

Group type: EXPERIMENTAL
Intervention: Tenidap sodium (120 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tenidap sodium
Number of subjects: 14
Study: 2286595

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid 500/125 mg three times daily
Number of subjects: 102
Study: 7042361

Group type: EXPERIMENTAL
Intervention: Indoprofen, 600 mg daily
Number of subjects: 44

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 3 g daily
Number of subjects: 44
Study: 31647267

Group type: EXPERIMENTAL
Intervention: DBT-skills group (DBT-S)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 84
Study: 29794828

Group type: EXPERIMENTAL
Intervention: Bictegravir, emtricitabine, and tenofovir alafenamide (after switching from initial treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bictegravir or dolutegravir with emtricitabine and tenofovir alafenamide (initial treatment)
Number of subjects: 0
Study: 27249205

Group type: EXPERIMENTAL
Intervention: Crushed eslicarbazepine acetate (800 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intact eslicarbazepine acetate (800 mg)
Number of subjects: 28
Study: 24792798

Group type: EXPERIMENTAL
Intervention: Microbial inoculant
Number of subjects: 3

Group type: COMPARATOR
Intervention: Without microbial inoculant
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Regrowth intervals (35, 45, 55, 65 days)
Number of subjects: 3
Study: 23300624

Group type: EXPERIMENTAL
Intervention: 10 µg iloprost
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 20 µg iloprost
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 20489176

Group type: EXPERIMENTAL
Intervention: Specialized long-term care at the stroke outpatient clinic
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care with general practitioner
Number of subjects: 163
Study: 18547173

Group type: EXPERIMENTAL
Intervention: Injection techniques that increase the dissection of the subepidermal plane (e.g., fanlike needle use, rapid injection, rapid flow rates, and higher volumes)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Injection techniques that increase epidermal damage or subcutaneous exposure (e.g., multiple punctures or deep subcutaneous injection)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Single injection correction, depth of injection, and NASHA product injected
Number of subjects: 283
Study: 16080579

Group type: COMPARATOR
Intervention: IL-2, 1.8 x 10(6) I.U. for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week interval (arm A)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: IL-2, 1.8 x 10(6) I.U. for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week interval plus oral RA, 0.5 mg/Kg (arm B)
Number of subjects: 112
Study: 12593726

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 225

Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Endogenously suppressed TSH follow-up group
Number of subjects: 225
Study: 10559528

Group type: EXPERIMENTAL
Intervention: 100 mg/kg oral methionine
Number of subjects: 29
Study: 8885917

Group type: EXPERIMENTAL
Intervention: Corticosteroids after treatment with ampicillin-sulbactam
Number of subjects: 77

Group type: COMPARATOR
Intervention: No corticosteroids (control group)
Number of subjects: 77
Study: 1947617

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 6833169

Group type: EXPERIMENTAL
Intervention: Parent advice package with experimenter assistance
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Parent advice package without experimenter assistance
Number of subjects: 9
Study: 30916121

Group type: EXPERIMENTAL
Intervention: 12.5% maltodextrin (200 mL, 2 h before anesthesia)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of ω‐3 PUFA (0.2 g/kg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Water (200 mL, 2 h before anesthesia) plus intraoperative infusion of ω‐3 PUFA (0.2 g/kg)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intraoperative infusion of ω‐3 PUFA
Number of subjects: 57
Study: 30392002

Group type: EXPERIMENTAL
Intervention: PHP-SMA
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (standard SMA)
Number of subjects: 19
Study: 27032700

Group type: EXPERIMENTAL
Intervention: Sequential FOLFIRI followed by docetaxel/cisplatin
Number of subjects: 1072

Group type: COMPARATOR
Intervention: 5-fluorouracil monotherapy
Number of subjects: 1072
Study: 25599306

Group type: EXPERIMENTAL
Intervention: Biochemical and pain biomarkers analysis including VICM, CRP, CRPM, CIIIM, CIIM, CIM, WOMAC, Lequesne, and pain catastrophizing scores.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cluster analysis applied to the optimal variable subset from principal component analysis.
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Pressure pain thresholds, temporal summation to pressure stimuli, and conditioning pain modulation measurements.
Number of subjects: 216
Study: 22289414

Group type: EXPERIMENTAL
Intervention: Mental subtraction
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Word association
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mental rotation
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of brain-teasers and dynamic imagery tasks
Number of subjects: 9
Study: 20336040

Group type: EXPERIMENTAL
Intervention: Combination of bacterial wound colonization and procalcitonin blood level > or =2 ng/ml
Number of subjects: 47
Study: 18476417

Group type: EXPERIMENTAL
Intervention: Qishen Huoxue Granule (QHG) plus conventional Western medicine
Number of subjects: 167

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 167
Study: 16498185

Group type: EXPERIMENTAL
Intervention: AirHeel (Aircast, Inc.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1st Step prefabricated foot insert (Wrymark, Inc)
Number of subjects: 50
Study: 12460350

Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No injection
Number of subjects: 121
Study: 10535397

Group type: EXPERIMENTAL
Intervention: Acipimox 250 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8946978

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 1684750

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg (SOD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 20 mg (SOD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (SS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cetirizine (SOD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hydroxyzine (SOD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6580840

Group type: EXPERIMENTAL
Intervention: Vindesine (VDS; 2 mg/m2 i.v., twice or once weekly) in combination with prednisolone (Pred; 40 mg/m2 p.o., daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Vincristine (VCR; 1.2 mg/m2 i.v., once weekly) in combination with prednisolone (Pred; 40 mg/m2 p.o., daily)
Number of subjects: 100
Study: 31004075

Group type: EXPERIMENTAL
Intervention: galcanezumab 150 mg biweekly for 12 weeks
Number of subjects: 217

Group type: COMPARATOR
Intervention: placebo biweekly for 12 weeks
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: galcanezumab
Number of subjects: 217

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 217
Study: 29973207

Group type: EXPERIMENTAL
Intervention: Audio + Video
Number of subjects: 15

Group type: COMPARATOR
Intervention: Audio Only
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of Audio + Video vs. Audio Only
Number of subjects: 15
Study: 26896964

Group type: EXPERIMENTAL
Intervention: Parental refusal to participate in trials
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Specific treatment arm rather than randomization
Number of subjects: 92
Study: 25132119

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (RYGB or SG)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Baseline adiponectin level
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Elevated adiponectin
Number of subjects: 40
Study: 22219517

Group type: EXPERIMENTAL
Intervention: Resveratrol (1, 1.5, or 2 g daily for 4 weeks)
Number of subjects: 10
Study: 19794285

Group type: EXPERIMENTAL
Intervention: Clodronate (100 mg every week) plus Calcium (500 mg daily) and Vitamin D3 (800 mg daily)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Supplements only (Calcium 500 mg daily and Vitamin D3 800 mg daily)
Number of subjects: 46
Study: 17932438

Group type: EXPERIMENTAL
Intervention: MTCT prophylaxis (3 short course zidovudine (AZT), 19 single-dose nevirapine (NVP), 5 both AZT and NVP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Single dose NVP for infants
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Exclusively formula-fed infants
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Mixed fed infants
Number of subjects: 41
Study: 17557989

Group type: EXPERIMENTAL
Intervention: High dairy consumption (3 portions of dairy each day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Low dairy consumption (1 portion of dairy each day)
Number of subjects: 58
Study: 14769077

Group type: EXPERIMENTAL
Intervention: Transient image presented for 33 ms during reading
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual events with varying saliency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abrupt auditory stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Display changes inside or outside the perceptual span
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive or attentional modulation
Number of subjects: 0
Study: 10944139

Group type: EXPERIMENTAL
Intervention: Risk index score >/= 21
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Predictive factors for low risk
Number of subjects: 756
Study: 9428114

Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sandimmun
Number of subjects: 38
Study: 8156864

Group type: EXPERIMENTAL
Intervention: Trial Coordinator activities including recruitment, screening, medical management, education and training, adherence and administration
Number of subjects: 21
Study: 2427851

Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Celiprolol 400 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 12
Study: 31974935

Group type: EXPERIMENTAL
Intervention: Fixated but irrelevant center item sharing features of the target item
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased sample sizes in Experiments 4 and 5
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linear search layout
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circular search layout
Number of subjects: 0
Study: 30511316

Group type: EXPERIMENTAL
Intervention: GB242
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reference Infliximab
Number of subjects: 48
Study: 28132762

Group type: EXPERIMENTAL
Intervention: Developed equations based on combinations of six to nine anthropometric variables.
Number of subjects: 601

Group type: COMPARATOR
Intervention: Previously published equations (e.g., Slaughter).
Number of subjects: 601
Study: 25569396

Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 32
Study: 23866738

Group type: EXPERIMENTAL
Intervention: 10-week yoga programme (1 class per week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no yoga intervention)
Number of subjects: 100
Study: 21074006

Group type: EXPERIMENTAL
Intervention: Anxious group (Experiment 1)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Anxious group (Experiment 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Neutral group (Experiment 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Happy group (Experiment 2)
Number of subjects: 150
Study: 19894388

Group type: EXPERIMENTAL
Intervention: XIAs No. 1 Sleeping Prescription
Number of subjects: 120

Group type: COMPARATOR
Intervention: Estazolam (1 mg) for 6 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Adverse reactions
Number of subjects: 120
Study: 17129304

Group type: EXPERIMENTAL
Intervention: Subhepatic administration of 20 mL of 0.5% bupivacaine just after the creation of pneumoperitoneum (group 2)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Subhepatic administration of 20 mL of 0.5% bupivacaine before pneumoperitoneum (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Subhepatic administration of 20 mL of 0.5% bupivacaine just before removal of the trocars (group 3)
Number of subjects: 80

Group type: COMPARATOR
Intervention: No local anesthetic (group 4)
Number of subjects: 80
Study: 15126514

Group type: EXPERIMENTAL
Intervention: Lifestyle modification aimed at weight loss (changes in diet and increased physical exercise)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 490
Study: 11453891

Group type: EXPERIMENTAL
Intervention: Flomoxef (1 g) at 09.00 h
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flomoxef (1 g) at 21.00 h
Number of subjects: 8
Study: 9556895

Group type: EXPERIMENTAL
Intervention: Perioperative antibiotics
Number of subjects: 80

Group type: COMPARATOR
Intervention: No antibiotics (Control)
Number of subjects: 80
Study: 8301766

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Friendly Visits (FVs)
Number of subjects: 194
Study: 2647666

Group type: EXPERIMENTAL
Intervention: Flunarizine 20 mg i.v.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29868715

Group type: EXPERIMENTAL
Intervention: Intervention group (notified prescribers)
Number of subjects: 877

Group type: COMPARATOR
Intervention: Control group (not notified prescribers)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 877
Study: 29018067

Group type: EXPERIMENTAL
Intervention: Midwives administering 600 µg misoprostol orally
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Physicians administering 600 µg misoprostol orally
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Midwives and physicians providing contraceptive counselling
Number of subjects: 1094

Group type: EXPERIMENTAL
Intervention: Midwives and physicians administering misoprostol
Number of subjects: 1094
Study: 25453392

Group type: EXPERIMENTAL
Intervention: Home telemonitoring care (TELE)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 205
Study: 23873553

Group type: EXPERIMENTAL
Intervention: Thymol + carvacrol at 200 mg/kg diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Thymol + carvacrol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 60
Study: 22161921

Group type: EXPERIMENTAL
Intervention: Large-head metal-on-metal bearing
Number of subjects: 100

Group type: COMPARATOR
Intervention: 28 mm diameter conventional metal-on-polyethylene bearing
Number of subjects: 100
Study: 19630538

Group type: EXPERIMENTAL
Intervention: Vaginal microbicide with protection properties
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Vaginal microbicide could prevent BV
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Vaginal microbicide could prevent vaginal odor
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Vaginal microbicide could prevent vaginal itching and burning
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Side effects of vaginal microbicide
Number of subjects: 408
Study: 16687907

Group type: EXPERIMENTAL
Intervention: Active compression decompression CPR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inspiratory impedance threshold valve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phased chest and abdominal compression‐decompression CPR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of diastolic blood pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of myocardial perfusion pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring of end‐tidal CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Number of subjects: 0
Study: 15753151

Group type: COMPARATOR
Intervention: Vitamin E (2000 IU/day, 2 years)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E (400 IU/day, 1 month) + Vitamin C (1000 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 0
Study: 11408497

Group type: EXPERIMENTAL
Intervention: RT-PCR detection of PSA mRNA
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: RT-PCR for PSA
Number of subjects: 193
Study: 9064059

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (2 tabs/day)
Number of subjects: 1473
Study: 7761669

Group type: EXPERIMENTAL
Intervention: Evening i.v. administration of erythropoietin (rHuEPO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Morning i.v. administration of erythropoietin (rHuEPO)
Number of subjects: 26
Study: 3554459

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylaxis
Number of subjects: 206
Study: 29970071

Group type: EXPERIMENTAL
Intervention: Universal home visits to pregnant women and their partners
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Universal home visits with added video edutainment
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 1800
Study: 27545119

Group type: EXPERIMENTAL
Intervention: SAR252067 (40, 120, 300, 600, 900, or 1200 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SAR252067 (40 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SAR252067
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25691681

Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1.0-3.0 g/day (4.0 ± 1.5 tablets/day)
Number of subjects: 644

Group type: COMPARATOR
Intervention: Sevelamer 2.4-14.4 g/day (10.1 ± 6.6 tablets/day)
Number of subjects: 644
Study: 23543427

Group type: EXPERIMENTAL
Intervention: Treadmill exercise test (TET) for elderly patients with CHD
Number of subjects: 110
Study: 21569380

Group type: COMPARATOR
Intervention: Normal Control (NC)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Alzheimer's Disease (AD)
Number of subjects: 59
Study: 18460643

Group type: EXPERIMENTAL
Intervention: Denosumab (escalating doses)
Number of subjects: 25
Study: 17974096

Group type: EXPERIMENTAL
Intervention: Sivelestat sodium hydrate
Number of subjects: 0
Study: 14507293

Group type: EXPERIMENTAL
Intervention: Group W1 (65% VO2max, 300 kcal in one daily walking bout)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group W2 (65% VO2max, 300 kcal in two daily walking bouts)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group W1 and W2 combined
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group W3 (55% VO2max, 300 kcal)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group W4 (45% VO2max, 300 kcal)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group W5 (55% VO2max, 200 kcal)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Group W6 (45% VO2max, 200 kcal)
Number of subjects: 255
Study: 11115683

Group type: EXPERIMENTAL
Intervention: Cochlear implant use
Number of subjects: 20
Study: 9210002

Group type: EXPERIMENTAL
Intervention: Acyclovir treatment
Number of subjects: 215
Study: 8425281

Group type: EXPERIMENTAL
Intervention: Holter monitoring (HM) combined with exercise testing
Number of subjects: 486

Group type: COMPARATOR
Intervention: Electrophysiological study (EPS)
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Holter monitoring (HM)
Number of subjects: 486
Study: 3303936

Group type: EXPERIMENTAL
Intervention: Terbutaline (11 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (9 patients)
Number of subjects: 20
Study: 31618698

Group type: EXPERIMENTAL
Intervention: Decongestive therapies
Number of subjects: 332

Group type: COMPARATOR
Intervention: Control group (nonobese HFpEF)
Number of subjects: 332
Study: 29550099

Group type: EXPERIMENTAL
Intervention: Battlefield acupuncture (BFA) plus standard care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 30
Study: 29138200

Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (offspring of women without GDM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Foetal echography
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Echocardiography (2-7 days after birth)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Carotid intima-media thickness measurement
Number of subjects: 200